Document Detail


Dornase alfa for cystic fibrosis.
MedLine Citation:
PMID:  20238314     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Dornase alfa is currently used to treat pulmonary disease (the major cause of morbidity and mortality) in cystic fibrosis.
OBJECTIVES: To determine whether the use of dornase alfa in cystic fibrosis is associated with improved mortality and morbidity compared to placebo or other mucolytics and to identify any adverse events associated with its use.
SEARCH STRATEGY: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches, handsearching relevant journals and abstracts from conferences.Date of the most recent search of the Group's Cystic Fibrosis Register: 17 July 2009.
SELECTION CRITERIA: All randomised and quasi-randomised controlled trials where dornase alfa was compared to placebo, standard therapy or another mucolytic.
DATA COLLECTION AND ANALYSIS: Authors independently assessed trials for inclusion criteria; the lead author and a colleague carried out analysis of methodological quality and data extraction.
MAIN RESULTS: The searches identified 43 trials, of which 15 met our inclusion criteria, including a total of 2469 participants. Three additional studies examined the healthcare cost from one of the clinical trials. Twelve studies compared dornase alfa to placebo or no dornase alfa treatment; one compared daily dornase alfa with hypertonic saline and alternate day dornase alfa; and two compared daily dornase alfa to hypertonic saline. Study duration varied from six days to two years. The number of deaths was not significant between treatment groups. Spirometric lung function improved in the treated groups, with significant differences at one month, three months, six months and two years, there was a non-significant difference at three years. There was no excess of adverse effects except voice alteration and rash, which were reported more frequently in one trial in the treated groups. Insufficient data were available to analyse differences in antibiotic treatment, inpatient stay and quality of life.
AUTHORS' CONCLUSIONS: There is evidence to show that therapy with dornase alfa over a one-month period is associated with an improvement in lung function in CF; results from a trial lasting six months also showed the same effect. Therapy over a two-year period (based on one trial) significantly improved FEV(1) in children and there was a non-significant reduction in the risk of infective exacerbations. Voice alteration and rash appear to be the only adverse events reported with increased frequency in randomised controlled trials.
Authors:
Ashley P Jones; Colin Wallis
Related Documents :
17253494 - Cilostazol for peripheral arterial disease.
18843734 - Antiviral therapy for ramsay hunt syndrome (herpes zoster oticus with facial palsy) in ...
16437474 - Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease.
17241924 - High-dose therapy with single autologous transplantation versus chemotherapy for newly ...
22005124 - Can we improve the reliability of the constant-murley score?
23543554 - Acupuncture for acute management and rehabilitation of traumatic brain injury.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Review     Date:  2010-03-17
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2010  
Date Detail:
Created Date:  2010-03-18     Completed Date:  2010-04-26     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD001127     Citation Subset:  IM    
Affiliation:
Institute of Child Health, University of Liverpool, Alder Hey Children's NHS Foundation Trust, Eaton Road, Liverpool, Merseyside, UK, L12 2AP.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Child
Child, Preschool
Cystic Fibrosis / drug therapy*
Deoxyribonuclease I / adverse effects,  therapeutic use*
Expectorants / adverse effects,  therapeutic use*
Humans
Infant
Randomized Controlled Trials as Topic
Saline Solution, Hypertonic / therapeutic use
Chemical
Reg. No./Substance:
0/Expectorants; 0/Saline Solution, Hypertonic; EC 3.1.21.1/DNASE1 protein, human; EC 3.1.21.1/Deoxyribonuclease I

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fibrinolytic agents for peripheral arterial occlusion.
Next Document:  Intravenous immunoglobulin for suspected or subsequently proven infection in neonates.